Abstract
The aim of this overview is to appraise the evidence on salivary biomarkers for H&N cancer diagnosis. The acronym PICOS was used to develop the eligibility criteria and the focused review question: are liquid biopsies (saliva biomarkers) reliable for cancer detection in H&N cancer patients? Electronic database search encompassed PubMed, EMBASE, Scopus, Cochrane Library, Web of Science, and LILACS. Risk of Bias (RoB) was assessed through AMSTAR 2. A total of 20 SRs were included. Only seven SRs were able to reach more solid conclusions around the retrieved findings by calculating the pooled sensitivity, specificity, and the overall area under the curve (AUC). Despite the limitations, significant RoB, and lack of test metrics in primary studies, all SRs recognize and encourage the potential role of saliva in the early diagnosis of oral cancer.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call